Vivimed Labs Balance Sheet Health
Financial Health criteria checks 0/6
Vivimed Labs has a total shareholder equity of ₹394.2M and total debt of ₹3.8B, which brings its debt-to-equity ratio to 960.3%. Its total assets and total liabilities are ₹9.9B and ₹9.5B respectively.
Key information
960.3%
Debt to equity ratio
₹3.79b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹37.62m |
| Equity | ₹394.23m |
| Total liabilities | ₹9.49b |
| Total assets | ₹9.88b |
Recent financial health updates
Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?
Mar 30
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Dec 14Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Nov 25
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?
Jul 31Recent updates
Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?
Mar 30Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Dec 14Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)
Jun 30Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)
Feb 22Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?
Jan 19Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Nov 25Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?
Sep 22Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?
Jul 31Financial Position Analysis
Short Term Liabilities: VIVIMEDLAB's short term assets (₹3.3B) do not cover its short term liabilities (₹4.2B).
Long Term Liabilities: VIVIMEDLAB's short term assets (₹3.3B) do not cover its long term liabilities (₹5.2B).
Debt to Equity History and Analysis
Debt Level: VIVIMEDLAB's net debt to equity ratio (950.7%) is considered high.
Reducing Debt: VIVIMEDLAB's debt to equity ratio has increased from 58% to 960.3% over the past 5 years.
Debt Coverage: VIVIMEDLAB's debt is not well covered by operating cash flow (9.3%).
Interest Coverage: Insufficient data to determine if VIVIMEDLAB's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/28 03:58 |
| End of Day Share Price | 2023/07/31 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivimed Labs Limited is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |
| Anil Burra | FirstCall Research |
| null null | K.R. Choksey Shares & Securities Private Ltd. |